21 Sep DevelRx and SCITEGRITY announce new partnership to streamline and improve drug abuse potential assessments and submissions
DevelRx, a company based in BioCity Nottingham, is delighted to announce a new partnership with Scitegrity (Discovery Park, Kent).
DevelRx is an internationally recognised consultancy business founded in 2020 that provides expert support on CNS (central nervous system) drug discovery and development to all sectors of the worldwide pharmaceutical and biotech industry. Key services include drug abuse evaluations of all centrally-acting drugs (regardless of the primary site of action). DevelRx facilitates regulatory submissions for drug-candidates by supporting preclinical drug development programs, preparing New Drug Applications (NDAs) / Market Authorisation Applications (MAAs) and abuse potential briefing documents (including 8-Factor analyses for the USA). As globally acknowledged experts in evaluating drug abuse risks, they provide a key service in de-risking early-stage projects in therapeutic indications where regulatory approval and controlled drug scheduling are major obstacles to commercial viability.
Scitegrity is a chemical legislation and trade compliance company founded in 2011 by former Pfizer Scientists and data managers. In 2014, Scitegrity, in conjunction with several Pharma companies, developed and launched Controlled Substances Squared, a market leading computational system that encodes controlled drug legislation from around the world. The system is trusted by world’s top pharmaceutical companies, CROs, and regulators to accurately and automatically identify if any chemical is considered controlled or regulated in over 28 countries.
Professor David Heal (Executive Director and cofounder of DevelRx) commented that the partnership between the two companies will give our clients access to the unique algorithms, data sets and expertise behind Scitegrity’s Controlled Substances Squared. This will provide robust, quantitative and reproducible 2-D chemical structure comparisons for new drug molecules in development versus drugs and chemical space with known abuse potential to include in our regulatory briefing documents.